Stockwatch: MonarchE And Tug-Of-War Drug Development
When One Drug Succeeds, Is It Curtains For The Competition?
Executive Summary
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?
You may also be interested in...
Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS
Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.